Nuyten Dimitry SA - 15 Dec 2024 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Reporting relationship: Chief Medical Officer
Issuer ticker: RCUS
Reported as of: 15 Dec 2024
Net transaction value: -$126,324
SEC form: 4
Accepted by SEC: 17 Dec 2024, 20:36:30 UTC
Prior SEC filing: 17 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Carolyn Tang, Attorney-in-Fact

Key filing fact

Nuyten Dimitry SA filed Form 4 for Arcus Biosciences, Inc. (RCUS) on 17 Dec 2024.

Key facts

This page summarizes Nuyten Dimitry SA's Form 4 filing for Arcus Biosciences, Inc. (RCUS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Dec 2024, 20:36.

Change

Previous filing in this sequence was filed on 17 Sep 2024.
Current net transaction value: -$126,324.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCUS transaction

Common Stock

Tax liability

Transaction value: $126,324
Shares: -7,856
Change %: -8.2%
Price: $16.08
Shares after: 87,518
Date: 15 Dec 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.